203 related articles for article (PubMed ID: 38001987)
1. Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer.
Bhoir S; Ogundepo O; Yu X; Shi R; De Benedetti A
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38001987
[TBL] [Abstract][Full Text] [Related]
2. Targeting Prostate Cancer, the 'Tousled Way'.
Bhoir S; De Benedetti A
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446279
[TBL] [Abstract][Full Text] [Related]
3. Interaction of TLK1 and AKTIP as a Potential Regulator of AKT Activation in Castration-Resistant Prostate Cancer Progression.
Khalil MI; Madere C; Ghosh I; Adam RM; De Benedetti A
Pathophysiology; 2021 Jul; 28(3):339-354. PubMed ID: 35366279
[TBL] [Abstract][Full Text] [Related]
4. The TLK1-MK5 Axis Regulates Motility, Invasion, and Metastasis of Prostate Cancer Cells.
Khalil MI; De Benedetti A
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497211
[TBL] [Abstract][Full Text] [Related]
5. TLK1-mediated MK5-S354 phosphorylation drives prostate cancer cell motility and may signify distinct pathologies.
Khalil MI; Singh V; King J; De Benedetti A
Mol Oncol; 2022 Jul; 16(13):2537-2557. PubMed ID: 35064619
[TBL] [Abstract][Full Text] [Related]
6. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
7. Generation of Phenothiazine with Potent Anti-TLK1 Activity for Prostate Cancer Therapy.
Singh V; Bhoir S; Chikhale RV; Hussain J; Dwyer D; Bryce RA; Kirubakaran S; De Benedetti A
iScience; 2020 Sep; 23(9):101474. PubMed ID: 32905878
[TBL] [Abstract][Full Text] [Related]
8. Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients.
Giesen A; Baekelandt L; Devlies W; Devos G; Dumez H; Everaerts W; Claessens F; Joniau S
Front Oncol; 2023; 13():1265812. PubMed ID: 37810962
[TBL] [Abstract][Full Text] [Related]
9. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
10. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
Voutsadakis IA; Stravodimou A
Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
[TBL] [Abstract][Full Text] [Related]
11. Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance.
Khalil MI; De Benedetti A
Cancer Drug Resist; 2022; 5(1):93-101. PubMed ID: 35582542
[TBL] [Abstract][Full Text] [Related]
12. Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.
Singh V; Jaiswal PK; Ghosh I; Koul HK; Yu X; De Benedetti A
Int J Cancer; 2019 Aug; 145(4):1055-1067. PubMed ID: 30737777
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Lethality Targeting Polθ.
Drzewiecka M; Barszczewska-Pietraszek G; Czarny P; Skorski T; Śliwiński T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741863
[TBL] [Abstract][Full Text] [Related]
14. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.
Mladenov E; Magin S; Soni A; Iliakis G
Front Oncol; 2013; 3():113. PubMed ID: 23675572
[TBL] [Abstract][Full Text] [Related]
15. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
Song L; McNeil EM; Ritchie AM; Astell KR; Gourley C; Melton DW
BMC Cancer; 2017 Dec; 17(1):864. PubMed ID: 29254481
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
17. Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
Xie T; Dickson KA; Yee C; Ma Y; Ford CE; Bowden NA; Marsh DJ
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230543
[TBL] [Abstract][Full Text] [Related]
18. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
[TBL] [Abstract][Full Text] [Related]
19. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
Shenoy TR; Boysen G; Wang MY; Xu QZ; Guo W; Koh FM; Wang C; Zhang LZ; Wang Y; Gil V; Aziz S; Christova R; Rodrigues DN; Crespo M; Rescigno P; Tunariu N; Riisnaes R; Zafeiriou Z; Flohr P; Yuan W; Knight E; Swain A; Ramalho-Santos M; Xu DY; de Bono J; Wu H
Ann Oncol; 2017 Jul; 28(7):1495-1507. PubMed ID: 28383660
[TBL] [Abstract][Full Text] [Related]
20. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
Lin ZP; Ratner ES; Whicker ME; Lee Y; Sartorelli AC
Mol Cancer Res; 2014 Mar; 12(3):381-393. PubMed ID: 24413181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
